These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 25482744)
1. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744 [TBL] [Abstract][Full Text] [Related]
2. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741 [TBL] [Abstract][Full Text] [Related]
3. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740 [TBL] [Abstract][Full Text] [Related]
4. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Morrissey CO; Gilroy NM; Macesic N; Walker P; Ananda-Rajah M; May M; Heath CH; Grigg A; Bardy PG; Kwan J; Kirsa SW; Slavin M; Gottlieb T; Chen S Intern Med J; 2014 Dec; 44(12b):1298-314. PubMed ID: 25482742 [TBL] [Abstract][Full Text] [Related]
5. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Chen SC; Sorrell TC; Chang CC; Paige EK; Bryant PA; Slavin MA Intern Med J; 2014 Dec; 44(12b):1315-32. PubMed ID: 25482743 [TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Rogers TR; Slavin MA; Donnelly JP Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422 [TBL] [Abstract][Full Text] [Related]
7. Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. Caira M; Trecarichi EM; Mancinelli M; Leone G; Pagano L Expert Rev Anti Infect Ther; 2011 Jul; 9(7):881-92. PubMed ID: 21810058 [TBL] [Abstract][Full Text] [Related]
8. Changes in the epidemiological landscape of invasive mould infections and disease. Lass-Flörl C; Cuenca-Estrella M J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Klingspor L; Saaedi B; Ljungman P; Szakos A Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371 [TBL] [Abstract][Full Text] [Related]
10. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). Lortholary O; Fernández-Ruiz M; Perfect JR J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667 [TBL] [Abstract][Full Text] [Related]
15. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials. Lee CH; Lin C; Ho CL; Lin JC Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872 [TBL] [Abstract][Full Text] [Related]
16. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Tragiannidis A; Dokos C; Lehrnbecher T; Groll AH Drugs; 2012 Mar; 72(5):685-704. PubMed ID: 22413762 [TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis of fungal infections in haematological patients: pro]. Glass B Dtsch Med Wochenschr; 2010 Sep; 135(38):1870. PubMed ID: 20842607 [No Abstract] [Full Text] [Related]
18. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Chau MM; Kong DC; van Hal SJ; Urbancic K; Trubiano JA; Cassumbhoy M; Wilkes J; Cooper CM; Roberts JA; Marriott DJ; Worth LJ Intern Med J; 2014 Dec; 44(12b):1364-88. PubMed ID: 25482746 [TBL] [Abstract][Full Text] [Related]
19. Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field. Douglas AP; Slavin MA Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1165-1177. PubMed ID: 27710140 [TBL] [Abstract][Full Text] [Related]
20. Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis. Reslan Z; Lindsay J; Kerridge I; Gellatly R Int J Clin Pharm; 2020 Dec; 42(6):1412-1418. PubMed ID: 33009604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]